Strategic Performance and Market Dynamics
-
XTENVI net product sales grew over 85% year-over-year, driven by a shift in physician behavior from treating only symptomatic cases to universal screening for collarettes.
-
Management attributes growth to increasing depth of prescribing, with nearly half of the 15,000 target eye care physicians now prescribing at least once a week.
-
The company is executing a ‘repeatable playbook’ for identifying underdiagnosed diseases with clear root causes, aiming to replicate XTENVI’s success in new therapeutic categories.
-
Market expansion is being fueled by evidence generation that links Demodex blepharitis to other conditions like chalazion and hordeolum, broadening the clinical utility for physicians.
-
Operational momentum is supported by a direct-to-consumer campaign that is exceeding ROI benchmarks and driving a 40% quarter-over-quarter increase in high-value website engagement.
-
Strategic positioning focuses on establishing XTENVI as the lasting standard of care, even as potential competitors enter the Phase II clinical landscape.
Growth Outlook and Strategic Initiatives
-
Full-year 2026 revenue guidance of $670 million to $700 million assumes a seasonal rebound in Q2, more modest growth in Q3, and robust growth in Q4 as patients meet insurance deductibles.
-
The deployment of a new Key Account Leader team in the third quarter is expected to catalyze incremental growth by targeting high-potential practices to further deepen utilization.
-
Management expects steady-state retreatment rates to reach approximately 20%, with current rates already trending in the mid-to-high teens.
-
Top-line data for the Phase II CALLIOPE trial in Lyme disease prevention is expected in 2027, while top-line data for the ocular rosacea program is anticipated in the first half of 2027.
-
The base case for the Lyme disease program involves delivering a robust Phase II data set before potentially transitioning the asset to a partner for large-scale Phase III trials.
Financial and Operational Context
-
Q1 results included a one-time $15 million regulatory milestone from partner Grand Pharma following TPO3 approval in Greater China.
-
First-quarter performance was impacted by typical seasonal dynamics, including deductible resets and severe winter weather in the Northeast U.S.
-
Gross margins are expected to remain stable at approximately 93% for the full year 2026.
-
Management noted that while China royalties are expected long-term, they will not be meaningful in 2026 or 2027 as the partner works to secure payer coverage.
Q&A Session Highlights
Competitive landscape and potential tolerability issues of rival assets
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.